NCT00561795View on ClinicalTrials.gov

Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Primary Peritoneal CarcinomaTumorEpithelial Ovarian CancerUterine DiseaseCervix DiseasesNeoplasms, OvarianCancer
Interventions
DRUG

pazopanib (GW786034)

800 mg orally once a day for 6 cycles

DRUG

carboplatin

IV over one hour every 3 weeks of 6 cycles

DRUG

paclitaxel

IV 175 mg/m\^2 given over 3 hours on day one of a 21 day cycle for six cycles

Trial Locations (5)

35043

GSK Investigational Site, Marburg

45122

GSK Investigational Site, Essen

65199

GSK Investigational Site, Wiesbaden

67085

GSK Investigational Site, Strasbourg

69373

GSK Investigational Site, Lyon

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY